Introduction: In a number of controlled trials it was established that mitoxantrone has a beneficial effect on disease progression in multiple sclerosis (MS) patients with a worsening disease course. The aim of this study was to investigate the use of mitoxantrone in clinical practice, and especially to describe predictive parameters of its effectiveness under these conditions. Objectives and methods: In a retrospective, open-label mitoxantrone study we analysed 94 MS patients (49) relapsing-remitting MS (RRMS), 41) secondary progressive MS and 10) primary progressive MS) who received monthly 20 mg i.v. mitoxantrone and 1 g i.v. methylprednisolone for six months, and selected as a criterion of effectiveness the percentage of patients with an Expanded Disability Status Scale (EDSS) improvement of at least one point (confirmed after one year) after stopping the treatment. A multivariate analysis was undertaken to assess the predictive value of five parameters on mitoxantrone effectiveness: (1) total number of relapses since disease onset and before treatment, (2) number of relapses within the past 24 months before treatment, (3) number of relapses in separate areas within the past 24 months before treatment, (4) active MRI scans (including Gd-enhanced lesions), and (5) clinical course of MS. Results: During the observation period from 1 January 1997 to 30 May 2000 more than 44) of the patients improved by one point or more on the EDSS (confirmed after one year), 39) remained stable and 17) deteriorated. In patients with a RRMS course three or more relapses within the past 24 months preceding treatment, and at least one Gd-enhancing lesion resulted in a strong relative benefit (i.e., relative risk) of mitoxantrone effectiveness. In contrast, total number of relapses since disease onset had no impact on disease evolution and disability progression. Multivariate analysis revealed the number of relapses in separate areas within the past 24 months before treatment as the strongest predictive parameter (PB/0.001). Conclusion: Mitoxantrone is effective in improving and stabilizing patients with a worsening MS course in routine clinical practice. Several strong predictive parameters of mitoxantrone effectiveness were investigated among which the number of relapses in separate areas within the past 24 months before treatment was found to be the strongest parameter to predict clinical improvement.
Edan G , Morrissey SP , Hartung HP.Use of mitoxantrone to treat multiple sclerosis. In Cohen JA , Rudick RA eds. Multiple sclerosis therapeutics, second edition. London, UK: Martin Dunitz , 2003: 403-426.
Fox ME , Smith PJ.Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone . Cancer Res1990; 50: 5813-5818 .
4.
Fidler JM , De Joy SQ , Smith III FR , Gibbons JJ.Selective immunomodulation by the antineoplastic agent mitoxantrone. Non-specific adherent suppressor cell derived from mitoxantrone treated mice . J Immunol1986; 136: 2747-2754 .
5.
Fidler JM , De Joy SQ , Gibbons JJ.Selective immunomodulation by the antineoplastic agent mitoxantrone. Suppression of B lymphocyte function . J Immunol1986; 137: 727-732 .
6.
Gbadamosi J , Buhmann C , Tessmer W , Moench A , Haag F , Heesen C.Effects of mitoxantrone on multiple sclerosis patients’ lymphocyte subpopulations and production of immunoglobulin, TNF-alpha and IL-10 . Eur Neurol2003; 49: 137-141 .
7.
Gorczyca W , Gong J , Ardelt B , Traganos F , Darzynkiewicz Z.The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents . Cancer Res1993; 53: 3186-3192 .
8.
Levine S , Saltzam A.Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone . J Neuroimmunol1986; 13: 175-181 .
9.
Lublin FD , Lavasa M , Viti C , Knobler RL.Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone . Clin Immunol Immunopathol1987; 45: 122-128 .
10.
Gonsette RE , Demonty L.Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients . Neurology1990; 40: 261-261 .
11.
Kappos L , Gold R , Kunstler E , Rohrbach E , Heun R , Städt Det al.Mitoxantrone (MX) in the treatment of rapidly progressive multiple sclerosis: a pilot study with serial gadolinium (GD)- enhanced MRI . Neurology1990; 40: 261-261 .
12.
Noseworthy JH , Lee D , Penman M , Hopkins M , Vandervoort MK , Karlik SJet al.A phase II evaluation of mitoxantrone in the treatment of progressive multiple sclerosis . Neurology1991; 41: 146-146 .
13.
Noseworthy JH , Hopkins MB , Vandervoort MK , Karlik SJ , Lee DH , Penman Met al.An open-trial evaluation of mitoxantrone in the treatment of progressive MS . Neurology1993; 43: 1401-1406 .
14.
Mauch E , Kornhuber HH , Krapf H , Fetzer U , Laufen H.Treatment of multiple sclerosis with mitoxantrone . Eur Arch Psychiatry Clin Neurosci1992; 242: 96-102 .
15.
Mauch E , Kornhuber HH.Immunosuppressive therapy of multiple sclerosis with mitoxantrone . Fortschr Neurol Psychiatry1993; 61: 410-417 .
16.
Krapf H , Mauch E , Fetzer U , Laufen H , Kornhuber HH.Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone . Neuroradiology1995; 37: 113-119 .
17.
McFarland HF , Stone LA , Calabresi PA , Maloni H , Bash CN , Frank JA.MRI studies of multiple sclerosis: implications for the natural history of the disease and for monitoring effectiveness of experimental therapies . Mult Scler1996; 2: 198-205 .
18.
Edan G , Miller D , Clanet M , Confavreux C , Lyon-Caen O , Lubetzki Cet al.Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria . J Neurol Neurosurg Psychiatry1997; 62: 112-118 .
19.
Bastianello S , Pozzilli C , D’Andrea F , Millefiorini E , Trojano M , Morino Set al.A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year . Can J Neurol Sci1994; 21: 266-270 .
20.
Millefiorini E , Gasperini C , Pozzilli C , D’Andrea F , Bastianello S , Trojano Met al.Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome . J Neurol1997; 244: 153-159 .
21.
Hartung HP , Gonsette R , Konig N , Kwiecinski H , Guseo A , Morrissey SPet al.Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multi-centre trial . Lancet2002; 360: 2018-2025 .
22.
Krapf H , Morrissey SP , Zenker O , Gonsette R , Hartung HP and the MIMS-Study Group . Mitoxantrone in progressive MS: a placebo-controlled, randomised, observer-blind European phase III multicenter study-MRI results . Mult Scler1998; 4: 380-380 .
23.
Koudriavtseva T , Thompson AJ , Fiorelli M , Gasperini C , Bastianello S , Bozzao Aet al.Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis . J Neurol Neurosurg Psychiatry1997; 62: 285-287 .
24.
Poser CM , Paty DW , Scheinberg L , McDonald I , Davis FA , Ebers GCet al.New diagnostic criteria for multiple sclerosis: guidelines for research protocols . Ann Neurol1983; 13: 227-231 .
25.
Confavreux C , Compston DAS , Hommes OR , McDonald WI , Thompson AJ.EDMUS, a European database for multiple sclerosis . J Neurol Neurosurg Psychiatry1992; 55: 671-676 .
26.
Kurtzke JF.Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology1983; 33: 1444-1452 .
